0. DOCID:3896 SCORE: 0.0031511091785644
DOCNO: 1192433
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Precancerous Conditions
QUALIFIER: pathology
QUALIFIER: etiology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: K Toyoshima K
AUTHOR: J Leighton J
PUBTYPE: Journal Article
JOURNALTITLE: Cancer research.
COUNTRY: UNITED STATES
TITLE: Bladder calculi and urothelial hyperplasia with papillomatosis in the rat following insertion of chalk powder in the bladder cavity with subsequent trauma of the bladder wall.
PUBDATE: 19751201
A suspension of chalk powder was injected into the cavity of the urinary bladder of Fischer 344 rats. Three weeks later rats were divided into 4 major groups and were given a submucosal injection. One group received a suspension of viable Chapman 4909 tumor cells, the 2nd group received a suspension of frozen-killed 4909 tumor cells, the 3rd group received a suspension of normal rat spleen cells, and the 4th group received cell-free fresh tissue culture medium. After 3 additional weeks urolithiasis was recognized in each experimental group. The incidence of calculi in the groups as listed above was 14 of 17, 6 of 11, 6 of 11, and 2 of 15, respectively. In control studies inocula consisted of tumor alone, i.e., without chalk powder. Inoculation of the 4909 rat bladder cancer cell line into the lumen of urinary bladders of rats did not result in any calculi after 3 weeks but did produce intramural tumor nodules and hyperplastic changes in adjacent host urothelium in 2 of 10 rats. The tumor inoculated in the submucosa of the bladder produced calculi and papillomas in 2 of 7 rats, and it produced intramural tumor nodules with adjacent hyperplasia of urothelium in all 7 rats.


1. DOCID:1189 SCORE: 0.00258202034869509
DOCNO: 1008991
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Leukocyte Count
DESCRIPTOR: Lymphocytes
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: C R Franks CR
AUTHOR: Y Williams Y
PUBTYPE: Journal Article
JOURNALTITLE: British journal of cancer.
COUNTRY: ENGLAND
TITLE: Prognostic value of peripheral lymphocyte count in hormone therapy of advanced breast cancer.
PUBDATE: 19761201
Peripheral lymphocyte counts were performed on 41 patients with advanced breast cancer, before starting treatment with oestrogens or androgens. Patients were seen at monthly intervals, and the response to treatment was independently assessed, using the criteria of the British Breast Group. In the patients treated with oestrogens and androgens, the successful responders were found to have significantly higher pre-treatment peripheral lymphocyte counts than the intermediate responders and failures. It is suggested that pre-treatment peripheral lymphocyte counts may have a prognostic value in assessing potential response to hormone therapy in patients with breast cancer.


2. DOCID:3705 SCORE: 0.00247984298213518
DOCNO: 414402
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: prevention & control
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
AUTHOR: D Byar D
AUTHOR: C Blackard C
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
PUBTYPE: Randomized Controlled Trial
JOURNALTITLE: Urology.
COUNTRY: UNITED STATES
TITLE: Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.
PUBDATE: 19771201
Animal studies have shown that metabolites of tryptophan can cause bladder cancer, and human observations reveal an appreciable incidence of abnormalities of tryptophan metabolism in patients with bladder cancer. It has been suggested that pyridoxine (vitamin B6) may correct this abnormality and prevent recurrences of superficial bladder cancers. Intravesical instillation of thiotepa has been used for more than fifteen years in the treatment of superficial bladder cancer, but no controlled trials have been done. We report here a prospective clinical trial of 121 patients with Stage I bladder cancer randomized to placebo, pyridoxine, or intravesical thiotepa. The percentages of patients with recurrences over the period of study were 60.4, 46.9, and 47.4 for the three groups, respectively, and did not differ significantly. However, if patients having recurrences during the first ten months or followed up less than ten months were excluded, pyridoxine was significantly better than placebo (P = 0.03). Thiotepa significantly reduced the recurrence rate compared with placebo (P = 0.016) or pyridoxine (P = 0.015). These results suggest that a new trial of pyridoxine should be undertaken in which the tryptophan metabolites are measured and that further study of intravesical instillation of chemotherapeutic agents is warranted.


3. DOCID:2529 SCORE: 0.00247784997504117
DOCNO: 49475
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: microbiology
QUALIFIER: genetics
AUTHOR: E Bone E
AUTHOR: B S Drasar BS
AUTHOR: M J Hill MJ
PUBTYPE: Journal Article
JOURNALTITLE: Lancet.
COUNTRY: ENGLAND
TITLE: Gut bacteria and their metabolic activities in familiar polyposis.
PUBDATE: 19750501
Earlier work had suggested that patients with large-bowel cancer can be characterized by carriage of clostridia capable of dehydrogenating the nucleus of steroids and by high faecal bile-acid concentrations. Familial polyposis is an inherited disease which untreated, will progress to cancer of the large bowel, and those affected might be expected to have these metabolic characteristics. However, enviromental factors seem to play no part in polyposis. Investigation of as yet unaffected children of known polyposis patients revealed that the gut flora of half of them did not degrade cholesterol in vivo andnor did flora from patients in whom polyposis had already been diagnosed. The reason for this is unknown, but if the same patients develop polyposis (i.e., they carry the abnormal gene) we would have a simple diagnostic test which could replace the continuing follow-up now required for the siblings and children of patients with polyposis.


4. DOCID:3245 SCORE: 0.00245831205337075
DOCNO: 128842
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Immunity
QUALIFIER: immunology
QUALIFIER: surgery
AUTHOR: J A Roth JA
AUTHOR: S H Golub SH
AUTHOR: E A Grimm EA
AUTHOR: F R Eilber FR
AUTHOR: D L Morton DL
PUBTYPE: Journal Article
JOURNALTITLE: Surgery.
COUNTRY: UNITED STATES
TITLE: Effects of operation on immune response in cancer patients: sequential evaluation of in vitro lymphocyte function.
PUBDATE: 19760101
The effect of operation on in vitro lymphocyte function in 35 cancer patients was studied. Lymphocyte proliferative responses to phytohemagglutinin (PHA), poke-weed mitogen (PWM), and concanavalin A (Con A) were measured by 3H-thymidine incorporation. Sheep red blood cell (SRBC) rosette formation also was quantitated. These tests were performed preoperatively and at 24 hours, one week, and 4 weeks postoperatively. Intra-abdominal and intrathoracic procedures, transfusions, and longer operating times depressed the lymphocyte proliferative response. However, an increased lymphocyte proliferative response was noted in sarcoma patients 24 hours postoperatively, possibly as a result of lowered tumor burden. Several of these changes still were evident 4 weeks after operation. Rosette formation also decreased significantly 24 hours postoperatively in patients who had intrathoracic or intra-abdominal procedures, but returned to preoperative levels after one week. In general, operation appears to cause transient depression of lymphocyte function in some cancer patients. However, lymphocyte function returns to normal by the fourth postoperative week in most patients.


5. DOCID:3584 SCORE: 0.00243976298655628
DOCNO: 338105
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: therapeutic use
QUALIFIER: prevention & control
QUALIFIER: surgery
AUTHOR: I Taylor I
AUTHOR: P Brooman P
AUTHOR: J T Rowling JT
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
PUBTYPE: Randomized Controlled Trial
JOURNALTITLE: British medical journal.
COUNTRY: ENGLAND
TITLE: Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial.
PUBDATE: 19771101
Fifty consecutive patients with colorectal cancer but no evidence of secondary deposits in the liver were included in an ongoing controlled clinical trial of adjuvant liver perfusion aimed at reducing the incidence of hepatic metastases. All patients had their primary tumour resected in the standard way. Twenty-six of the patients served as controls, and 24 received fluorouracil, 1 g daily, as a continuous infusion into the portal venous system during the first seven days after operation. The patients were matched for age, sex, and site and stage of the disease. The immediate postoperative mortality and morbidity did not differ significantly between the two groups. During the follow-up period (mean duration 15.5 months), however, six deaths occurred in the control group and only one in the perfusion group. At necropsy four of the controls had multiple liver metastases. Two of the surviving controls developed evidence of liver metastases, and two had a local recurrence. No patient in the perfusion group developed evidence of hepatic metastases. These initial results suggest that adjuvant portal venous perfusion with fluorouracil may reduce the incidence of liver metastases in colorectal cancer.


6. DOCID:3961 SCORE: 0.00242581491613524
DOCNO: 1026759
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Breast Neoplasms
DESCRIPTOR: Pregnancy Complications
AUTHOR: M Dargent M
AUTHOR: M Mayer M
AUTHOR: J Lansac J
AUTHOR: J L Carret JL
PUBTYPE: Journal Article
JOURNALTITLE: Journal de gynécologie, obstétrique et biologie de la reproduction.
COUNTRY: FRANCE
TITLE: [Breast cancer and pregnancy. Apropos of 96 cases followed for 3 and 1/2 years at the Centre Léon Bérard, Lyons]
PUBDATE: 19760901
96 cases where cancer of the breast and pregnancy were associated have been studied at the Léon Bérard Centre of Lyon with a follow-up of at least 3 years. Those patients who had a malignant tumour of the breast, which was treated, and then became pregnant (19 cases) were not made any worse (79 per cent survival in 5 years). This was quite independent of the outcome of the pregnancy. On the other hand, those women (54 cases) in which the cancer was discovered and treated during pregnancy had a far worse prognosis (20 per cent survival in 5 years). This prognosis was made worse by the discovery of the cancer in the third trimester of the pregnancy, and by the presence of lymph node involvement, by termination of pregnancy and by weaning. When malignant tumours were discovered during breast-feeding or weaning (23 cases) the prognosis was equally bad (23 per cent survival in 3 years). The authors discuss the frequency of the association of cancer of the breast and pregnancy, as well as the different factors in the prognosis. They attempt to outline the management that should be carried out in the light of recent publications on this subject.


7. DOCID:3817 SCORE: 0.00229966009154712
DOCNO: 300876
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Ultraviolet Rays
QUALIFIER: immunology
AUTHOR: M S Fisher MS
AUTHOR: M L Kripke ML
PUBTYPE: Journal Article
JOURNALTITLE: Proceedings of the National Academy of Sciences of the United States of America.
COUNTRY: UNITED STATES
TITLE: Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis.
PUBDATE: 19770401
Chronic irradiation of mice with ultraviolet (UV) light produces a systemic alteration of an immunologic nature. This alteration is detectable in mice long before primary skin cancers induced by UV light begin to appear. The alteration results in the failure of UV-irradiated mice to reject highly antigenic, transplanted UV-induced tumors that are rejected by unirradiated syngeneic recipients. The immunologic aspect of this systemic alteration was demonstrated by transferring lymphoid cells from UV-irradiated mice to lethally x-irradiated recipients. These recipeints were unable to resist a later challenge with a syngeneic UV-induced tumor, whereas those given lymphoid cells from normal donors were resistant to tumor growth. Parabiosis of normal mice with UV-irradiated mice, followed by tumor challenge of both parabionts with a UV-induced tumor, resulted in the growth of the challenge tumors in both UV-irradiated and unirradiated mice. Splenic lymphocytes from tumor-implanted UV-treated mice were not cytotoxic in vitro against UV-induced tumors, whereas under identical conditions cells from tumor-implanted, unirradiated mice were highly cytotoxic. Our findings suggest that repeated UV irradiation can circumvent an immunologic mechanism that might otherwise destroy nascent UV-induced primary tumors that are strongly antigenic.


8. DOCID:3769 SCORE: 0.0020572436841058
DOCNO: 955744
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: A S Morrison AS
AUTHOR: C R Lowe CR
AUTHOR: B MacMahon B
AUTHOR: B Ravnihar B
AUTHOR: S Yuasa S
PUBTYPE: Journal Article
JOURNALTITLE: International journal of cancer. Journal international du cancer.
COUNTRY: DENMARK
TITLE: Some international differences in treatment and survival in breast cancer.
PUBDATE: 19760901
In a recent study, 5-year survival rates for breast cancer patients in Boston (Massachusetts), Glamorgan (Wales), Slovenia (Yugoslavia) and Tokyo (Japan) were 57.3%, 49.5%, 41.9% and 74.9%, respectively. In this report, data are presented on the types of treatment used in the four areas and on the relationship of differences in treatment practices to the differences in survival rates. Generally, surgically treated patients who also had radiotherapy had lower survival rates than patients in the same area who had similar operations without radiotherapy. In each area, the survival rate was higher for patients who had radical mastectomy than for those who had simple mastectomy. The Japanese patients had the highest survival rate within nearly every treatment and extent-treatment category. Thus, the high survival rate of these patients was not explained by the variables considered. Survival differences between Boston, Glamorgan and Slovenia were largely explained by differences in extent of disease and type of treatment. As the nature of the treatment--survival trends was consistent with the interpretation that treatment tended to be selected according to apparent prognosis, the degree to which treatment customs were determinants of the differences in survival rate among the three areas is uncertain.


9. DOCID:2784 SCORE: 0.00205719749183791
DOCNO: 50247
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: administration & dosage
AUTHOR: N Fukuda N
AUTHOR: M Urano M
AUTHOR: M Endo M
AUTHOR: K Ando K
PUBTYPE: Journal Article
JOURNALTITLE: Gann = Gan.
COUNTRY: JAPAN
TITLE: Optimum fractionation regimen for bleomycin treatment.
PUBDATE: 19750401
A theoretical analysis was made on the optimum Bleomycin treatment regimen on the basis of the "binding-saturation model" which was proposed for the Bleomycin dose-cell survival relation. The surviving fraction of tumor cells decreased as a function of the number of fractionated treatments up to the optimum fractionation number if the tumor was treated with the same total dose. The effect of cellular sensitivity to the antibiotic, tumor doubling time, treatment interval, and total doses on the optimum regimen was analyzed. The importance of treatment interval and tumor doubling time was emphasized and the short treatment interval was recommended for the clinical use of this antibiotic. The optimum number of fractions increased linearly with the increase of the total dose while the optimum single dose was independent of the total dose. A concept of the tumor control probability of tumors treated with the optimum fractionation regimen was introduced and implications of these analyses in the clinical cancer chemotherapy were discussed.


10. DOCID:2516 SCORE: 0.00202644924705955
DOCNO: 974477
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: radiotherapy
AUTHOR: E U Bieler EU
AUTHOR: T Schnabel T
AUTHOR: J Knobel J
PUBTYPE: Clinical Trial
PUBTYPE: Controlled Clinical Trial
PUBTYPE: Journal Article
JOURNALTITLE: The British journal of radiology.
COUNTRY: ENGLAND
TITLE: Persisting cyclic ovarian activity in cervical cancer after surgical transposition of the ovaries and pelvic irradiation.
PUBDATE: 19761001
The effect of surgical transposition of the ovaries on gonadal function was investigated in ten young women with carcinoma of the uterine cervix, stages I and II. Gonadotrophin-, oestradiol- and progesterone-levels were determined before and during pelvic irradiation. A control group consisted of seven patients with cervical cancer who did not undergo ovaria transposition. In the control group gonadotrophins began to rise after radiation doses of 560-2400 rad (FSH) and 1130-2600 rad (LH) respectively. The excessive secretion was not seen in patients who had ovarian lifting. Ovulatory cycles occurred during or after pelvic irradiation in seven women of the study group, either spontaneously or induced by clomiphene treatment. This indicates that transposition preceding radiotherapy is an effective means of preserving ovarian secretion in young women in whom malignancies of the pelvic region demand irradiation.


11. DOCID:3176 SCORE: 0.00198908420212429
DOCNO: 870174
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Neoplasms, Multiple Primary
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: M Lapes M
AUTHOR: L Iozzi L
AUTHOR: W D Ziegenfus WD
AUTHOR: K Antoniades K
AUTHOR: R Vivacqua R
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: Familial testicular cancer in a father (bilateral seminoma-embryonal cell carcinoma) and son (teratocarcinoma): a case report and review of the literature.
PUBDATE: 19770501
Familial testicular neoplasia is reported in a father and his son. This represents only the fifth published case of father-son testicular cancer. The father had bilateral testicular seminoma with embryonal cell elements while the son had teratocarcinoma. The clinical significance of familial testicular neoplasia is discussed and the subject of father and son testicular cancer is reviewed. This case of father-son testicular neoplasia illustrates the following important points: 1) there is a continuing need to document and describe each case of familial testicular cancer in order to better evaluate the pathogenesis of this familial occurrence; 2) prospective genetic and laboratory studies will be needed to definitively clarify the specific factors involved in the familial clustering or transmission of this type of cancer; and 3) this tendency for testicular cancer to affect multiple kindred must be considered in the proper guidance and counseling of affected patients and their high-risk family members.


12. DOCID:2812 SCORE: 0.00197455760219407
DOCNO: 879871
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Common Bile Duct
QUALIFIER: complications
QUALIFIER: complications
QUALIFIER: complications
AUTHOR: R Tsuchiya R
AUTHOR: N Harada N
AUTHOR: T Ito T
AUTHOR: M Furukawa M
AUTHOR: I Yoshihiro I
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Annals of surgery.
COUNTRY: UNITED STATES
TITLE: Malignant tumors in choledochal cysts.
PUBDATE: 19770701
Between 1960 and 1975, 17 patients with congenital cystic dilatation of the common bile duct (choledochal cyst) were treated and three were associated with malignant tumors in the cysts and one was with carcinoma of the gallbladder. Preoperative diagnosis of adenocarcinoma in the choledochal cyst was established in one patient by cytologic examination of the bile which was obtained during the procedure of endoscopic pancreaticocholangraphy (EPCG) and percutaneous transhepatic cholangiography (PTC). Definitive treatment of the choledochal cysts associated with malignant tumors in the biliary tract was accomplished by excision of the cysts with tumor and choledochojejunostomy in two patients, by cystoduodenostomy following external drainage in one and by cholecystectomy with resection of invaded transverse colon in one with cancer of the gallbladder. Successful excision of choledochal cysts in 11 patients including three cases associated with malignant tumors in the biliary tract during the last 15 year period is the basis of this report.


13. DOCID:3946 SCORE: 0.00196312706961444
DOCNO: 183539
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
AUTHOR: B Pierquin B
PUBTYPE: Historical Article
PUBTYPE: Journal Article
JOURNALTITLE: AJR. American journal of roentgenology.
COUNTRY: UNITED STATES
TITLE: The destiny of brachytherapy in oncology.
PUBDATE: 19760901
At the invitation of the American Radium Society, Pierquin reviews his very large experience with continuous low dose rate irradiation of cancer. The target volume is treated with 6,000-7,000 rad in 3-10 days at a dose rate of 30-100 rad/hr. Preference for continuous low dose rate irradiation is based on the earlier work of Jean Pierquin, Georges Richard, Claudius Regaud, and Ralston Paterson with radium sources. Afterloading techniques with iridium-192 have been substituted allowing safer and more precise placement. An accumulated experience with 5,000 patients over the past 15 years permits conclusions that the techniques are safe, easy, inexpensive, and effective for tumors accessible to direct instrumentation. Dosimetry is based on the Paris system. Standardizing upon a dose of 7,000 rad, Pierquin concludes there is an isoeffect of continuous radiation at low dose rates of 25-100 rad/hr. The differential effect on tumor versus healthy tissue is impressive even when large volumes are irradiated, as in neck adenopathy. Stemming from this experience, three trials have been carried out of low dose rate teletherapy with cobalt-60 sources in oral cavity and oropharynx tumors, delivering 7,000 rad at rates of 90-100 rad/hr. Pierquin hopes for the same very high local control rates (in the order of 95%)achieved by iridium-192 endoradiotherapy of accessible T1, T2, T3, and T4 cancers.


14. DOCID:3950 SCORE: 0.00193376317720849
DOCNO: 238735
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: blood
QUALIFIER: blood
AUTHOR: C W Young CW
AUTHOR: S Hodas S
AUTHOR: W Dessources W
AUTHOR: L Korngold L
PUBTYPE: Journal Article
JOURNALTITLE: Cancer research.
COUNTRY: UNITED STATES
TITLE: Observations on trace proteins in plasma of febrile patients by cationic disc electrophoresis in acrylamide gel at pH 3.8.
PUBDATE: 19750801
Cationic disc electrophoresis at pH 3.5 in 6 M urea-containing acrylamide gels permits analysis of plasma and other body fluids for the presence of trace proteins with pI greater than or equal 5 and M.W. less than 60,000. These charge and size characteristics would include rabbit and human granulocytic pyrogen, human monocytic pyrogen and, by inference, other similar candidate pyrogenic proteins. Semiquantitation of the trace protein content can be achieved by densitometric scanning of gels stained with Amido schwarz. Duplicate analyses were performed on plasma samples from 133 individuals: normal, 15; afebrile advanced cancer, 18; afebrile Hodgkin's disease, 30; febrile Hodgkin's disease, 33; other febrile lymphoma, 13; febrile advanced cancer without infection, 12; and pyogenic fever, 12. Plasma from most of the febrile patients, particularly from febrile Hodgkin's disease patients, contained trace proteins not detectable in the afebrile individuals studied. In patients with Hodgkin's disease the quantity of trace proteins present in plasma correlated well with overall severity of Hodgkin's pyrexia, but not with spontaneous hr to hr fluctuations in the fever. Marked reduction in plasma levels of the trace proteins occurred with response to antitumor therapy. Elevated plasma levels of these proteins can be induced by intratumoral inoculation of Bacillus Calmette-Guérin. They appear concomitant with the febrile response.